Autres langues Avacta Group Plc

Actions

AVCT

GB00BYYW9G87

Recherche biotechnologique et médicale

Temps Différé London S.E. Autres places de cotation 15:01:12 19/05/2026			Varia. 5j.	Varia. 1 janv.
83,78 ^GBX	-0,85 %		-1,75 %	+44,83 %

12:08	Avacta Group : la perte annuelle se creuse dans l'attente des résultats d'essais cliniques en oncologie	AN
08:52	Avacta Therapeutics publie un chiffre d'affaires de 6,31 millions de livres pour l'exercice clos le 31 décembre 2025	RE

Autres langues

12:08	Avacta Group annual loss widens as cancer treatment trial results loom
08:52	Avacta Therapeutics reports group revenues of £6.31 million for year ended December 31, 2025
08:46	Avacta Group continues to explores multiple commercial opportunities with strategic partners
08:15	Unaudited Preliminary Results for the Year Ended December 31, 2025
06/05	Avacta : presents new comparisons of pre\|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026
06/05	Avacta presents new comparisons of pre\|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026
06/05	Avacta Therapeutics Presents New Comparisons Of Pre\|CISION Payload Release Versus Approved ADCs And AVA6207 Dual Payload Delivery
21/04	Vaalco says remainder of 2026 to be "very profitable"
21/04	Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre\|CISION® delivery platform
21/04	Avacta Therapeutics Presents Favorable Data for AVA6103 and Showcases Dual Payload pre\|CISION Platform At AACR 2026
14/04	Avacta CEO Christina Coughlin Named as One of In Vivo's 2026 Rising Leaders
09/04	Somero Enterprises extends buyback to USD6.0 million
09/04	Avacta hails "important milestones" in start of "transformative" year
08/04	Avacta : Announces 2026 Science Day Event
31/03	Avacta announces first patient treated in Phase 1 FOCUS-01 trial of FAP-Exd (AVA6103) - a sustained-release pre\|CISION® exatecan peptide drug conjugate
31/03	Avacta Therapeutics Announces First Patient Treated In Phase 1 Focus-01 Trial Of FAP-Exd
27/03	Avacta Therapeutics Conditionally Raises GBP10 Million via Share Placing, Subscription
27/03	Avacta raises GBP10 million in equity for clinical tests
27/03	Avacta : Results of Oversubscribed Placing and Subscription
27/03	Avacta Therapeutics says placing & subscription represent 3.60% of issued share capital
27/03	Avacta to Raise GBP10 Million via Equity Placing, Subscription
26/03	Avacta Therapeutics proposed placing via accelerated bookbuild & subscription to raise about £10 million
26/03	Avacta : Proposed Placing via an accelerated bookbuild and Subscription to raise approximately £10 million
17/03	Avacta Announces Preclinical and Translational Presentations of pre\|CISION® Platform Candidates at the 2026 AACR Annual Conference
16/03	Avacta opens phase 1 trial for conjugate's efficacy regarding tumours